Myelitis infect immunocompromised hosts such as Candida species, Aspergillus species, and zygomycetes. Parasitic species infect human hosts through larvae that penetrate the skin. Then they enter the lymphatic and circulatory system, and migrate to liver and lung. Some reach the spinal cord. Parasitic infections have been reported with Schistosoma species, "Toxocara canis", Echinococcus species, "Taenia solium", "Trichinella spiralis", and Plasmodium species. In 2016 it was identified in Mayo clinic an autoimmune form of myelitis due to the presence of anti-GFAP autoantibodies. Immunoglobulins directed against the α-isoform of glial fibrillary acidic protein (GFAP-IgG) predicted an special meningoencephalomyelitis termed autoimmune GFAP Astrocytopathy that
Myelitis firm diagnosis. Rarely, a biopsy of a mass lesion may become necessary when the cause is uncertain. However, in 15–30% of people with subacute or chronic myelitis, a clear cause is never uncovered. Since each case is different, the following are possible treatments that patients might receive in the management of myelitis. High-dose intravenous methyl-prednisolone for 3–5 days is considered as a standard of care for patients suspected to have acute myelitis, unless there are compelling reasons otherwise. The decision to offer continued steroids or add a new treatment is often based on the clinical course and MRI appearance at